ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO0169

Type 2 Conventional Dendritic Cells Drive Necroinflammation in Postischemic Acute Kidney Injury and Disease

Session Information

  • AKI: Mechanisms - 2
    November 07, 2025 | Location: Exhibit Hall, Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Acute Kidney Injury

  • 103 AKI: Mechanisms

Authors

  • Lichtnekert, Julia, Division of Nephrology, Department of Medicine IV, Hospital of LMU, Munich, Germany
  • Long, Hao, Division of Nephrology, Department of Medicine IV, Hospital of LMU, Munich, Germany
  • Borisova, Kristina Ognianova, Division of Nephrology, Department of Medicine IV, Hospital of LMU, Munich, Germany
  • Steiger, Stefanie, Division of Nephrology, Department of Medicine IV, Hospital of LMU, Munich, Germany
  • Anders, Hans J., Division of Nephrology, Department of Medicine IV, Hospital of LMU, Munich, Germany
Background

Ischemia-reperfusion injury (IRI) is a frequent cause of acute kidney injury and disease (AKI/AKD), which can lead to acute tubular necrosis and irreversible loss of kidney function. Kidney-resident conventional dendritic cells (cDCs) contribute to all phases of AKI but separate into several functional subsets. Type 1 conventional dendritic cells (cDC1s) have renoprotective effects, as their deficiency exacerbates inflammation and injury in the IRI-induced AKI/AKD model. We hypothesized that type 2 conventional dendritic cells (cDC2s) may have an opposite role in AKI.

Methods

We performed unilateral IRI (uIRI) surgery in mice that lack interferon regulatory factor 4 (IRF4) in DC lineage Clec9a-positive cells (Clec9a-cre; IRF4fl/fl) and wild-type mice. Single-cell suspensions were isolated from injured kidneys and analysed by flow cytometry to detect kidney mononuclear phagocytes. In vitro we generated bone marrow derived CD103+ dendritic cells by FLT3 ligand-rich supernatant and GM-CSF. We generated bone marrow-derived DCs from wild-type mice and Clec9a-cre; IRF8fl/fl mice to obtain cDC1-like and cDC2-like cells.

Results

IRF4 deletion on DC lineage cells reduced the kidney-resident population of cDC2s without affecting resident cDC1s compared to control mice. Clec9a-cre; IRF4fl/fl-mice showed at day 1 and 5 of uIRI reduced tubular cell injury, improved kidney function, and recovery. This was associated with elevated expression of anti-inflammatory cytokines, decreased pro-inflammatory cytokines, neutrophil chemoattractant expression (CXCL-2), recruitment of neutrophils, and differentiation of Th2 and Th17 cells, leading to reduced acute tubular cell death. In addition, bone marrow-derived DCs from wild-type mice and Clec9a-cre; IRF8fl/fl mice were separately induced and differentiated into cDC1-like and cDC2-like cells, then stimulated with LPS in vitro. cDC2-like cells exhibited a higher proinflammatory cytokine secretion profile, with increased levels of CXCL-2 compared to cDC1-like cells, consistent with the in vivo findings.

Conclusion

Together, cDC2s have an immunoregulatory role in AKI/AKD and could serve as a potential therapeutic target for improving kidney injury and inflammation during AKI.

Funding

  • Government Support – Non-U.S.

Digital Object Identifier (DOI)